Burge Ulukan

Hollings researchers turn chemoresistance into a target by blocking LOX first

The Hollings group puts lysyl oxidase inside the cancer cell, running its mitochondria, and reports that shutting it down leaves a backup survival pathway a second drug can close. The work is preclinical, and thinly quantified.